Results 1 to 10 of about 50,442 (246)

Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival [PDF]

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22
Terry J Fry, Amanda J Novak, Alexander W Rankin, Catherine Pham-Danis, Etienne Danis, M Eric Kohler   +5 more
doaj   +2 more sources

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.

PLoS ONE, 2021
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely.
Christine Ambrose, Lihe Su, Lan Wu, Fay J Dufort, Thomas Sanford, Alyssa Birt, Benjamin J Hackel, Andreas Hombach, Hinrich Abken, Roy R Lobb, Paul D Rennert   +10 more
doaj   +1 more source

Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy

Molecular Therapy: Oncolytics, 2020
Chimeric antigen receptor (CAR) T cell therapy has had limited efficacy for solid tumors, largely due to a lack of selectively and highly expressed surface antigens.
Amin Aalipour, Fabrice Le Boeuf, Matthew Tang, Surya Murty, Federico Simonetta, Alexander X. Lozano, Travis M. Shaffer, John C. Bell, Sanjiv S. Gambhir   +8 more
doaj   +1 more source

RELIABLE FLOW CYTOMETRY METHOD FOR MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA AFTER BLINATUMOMAB THERAPY

Hematology, Transfusion and Cell Therapy, 2023
Introduction: The recent active use of immunotherapy based on CD19/CD3 bispecific T-cell engager (blinatumomab), brings significant problems on monitoring Minimal Residual Disease (MRD) based on Multiparameter Flow Cytometry (MFC), due to possible CD19 ...
RM Pontes, FM Furtado, SCR Franco, RA Toscano, TF Nunes, ACS Dias, JCM Cordoba, ACMDS Junior, R Camargo, IMM Quezado   +9 more
doaj   +1 more source

TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss

Cancer Cell International, 2021
Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li, Qing Zhang, Zhi Liu, Huijuan Shen, Yangmin Zhu, Zhao Zhou, Wen Ding, Siqi Han, Jie Zhou, Ruiming Ou, Min Luo, Shuang Liu   +11 more
doaj   +1 more source

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. [PDF]

PLoS ONE, 2013
Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-tumor responses. Most infuse T cells genetically modified to express a chimeric antigen receptor (CAR) with specificity derived from the scFv region of a CD19 ...
Bipulendu Jena, Sourindra Maiti, Helen Huls, Harjeet Singh, Dean A Lee, Richard E Champlin, Laurence J N Cooper   +6 more
doaj   +1 more source

Altered Phenotype and Enhanced Antibody-Producing Ability of Peripheral B Cells in Mice with Cd19-Driven Cre Expression

Cells, 2022
Given the importance of B lymphocytes in inflammation and immune defense against pathogens, mice transgenic for Cre under the control of Cd19 promoter (Cd19Cre/+ mice) have been widely used to specifically investigate the role of loxP-flanked genes in B ...
Ying Zhao, Sai Zhao, Xiao-Yuan Qin, Ting-Ting He, Miao-Miao Hu, Zheng Gong, Hong-Min Wang, Fang-Yuan Gong, Xiao-Ming Gao, Jun Wang   +9 more
doaj   +1 more source

Antigen-specific cytokine profiles for pulmonary Mycobacterium avium complex disease stage diagnosis

Frontiers in Immunology, 2023
IntroductionControlling pulmonary Mycobacterium avium complex (MAC) disease is difficult because there is no way to know the clinical stage accurately. There have been few attempts to use cell-mediated immunity for diagnosing the stage.
Yoshiro Yamashita, Yoshiro Yamashita, Ikkoh Yasuda, Ikkoh Yasuda, Takeshi Tanaka, Toru Ikeda, Mayumi Terada, Masahiro Takaki, Yoshiko Tsuchihashi, Norichika Asoh, Yukiko Ohara, Shymaa Enany, Shymaa Enany, Haruka Kobayashi, Sohkichi Matsumoto, Konosuke Morimoto, Konosuke Morimoto   +16 more
doaj   +1 more source

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells

Translational Oncology, 2023
Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar ...
Shang-Ju Wu, Chien-Ting Lin, Cheng Hao Liao, Chun-Ming Lin   +3 more
doaj   +1 more source

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells

Biomedicines, 2023
Background: Therapeutic options for CD19+ relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed.
Audrey Grain, Jocelyn Ollier, Thierry Guillaume, Patrice Chevallier, Baptiste Le Calvez, Marion Eveillard, Béatrice Clémenceau   +6 more
doaj   +1 more source